Related Experiment Video
Updated: Feb 26, 2026

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
Indication-specific pricing of pharmaceuticals in the US healthcare system
Steven D Pearson1, William B Dreitlein1, Chris Henshall2
1Institute for Clinical & Economic Review, Two Liberty Square, 9th Floor, Boston, MA 02109, USA.
Aim:
To explore the potential of indication-specific pricing (ISP) of pharmaceuticals and to discuss prospects for implementation in the US healthcare system.
Materials & Methods:
The Institute for Clinical and Economic Review convened a policy forum with 44 healthcare leaders from 22 payer and life sciences companies. Models of ISP were discussed.
Results:
Payers and drug manufacturers saw the potential benefits of an ISP system that balances affordability for payers, sustainability for manufacturers and access for patients. The US healthcare system presents many challenges to implementation, including potential conflicts with existing pricing policies (Medicaid Best Price, average sales price and 340B) and insufficient data systems and analytic capabilities.
Conclusion:
Possible solutions and policy recommendations for payers and manufacturers are provided.
More Related Videos
Related Concept Videos
Drug Nomenclature
Drug Products: Biologics, Biosimilars and Interchangeables
Bioequivalence of Drugs: Drugs with Multiple Indications
Dosage Regimen: Individualization
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Pharmaceutical Equivalents

